AZD8871

DRUG3 trials

Sponsors

AstraZeneca

Conditions

Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease - COPD

Phase 1

Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Subjects

CompletedNCT02814656

AstraZenecaChronic Obstructive Pulmonary Disease

Start: 2016-06-22End: 2016-11-28Updated: 2019-02-15

Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Male Japanese Subjects

CompletedNCT03159442

AstraZenecaChronic Obstructive Pulmonary Disease - COPD

Start: 2017-06-19End: 2017-10-13Updated: 2017-10-25

Phase 2

A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases.

CompletedNCT03645434

AstraZenecaChronic Obstructive Pulmonary Disease

Start: 2018-10-10End: 2019-08-07Updated: 2020-12-17

Related Papers

The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD

European Respiratory Journal2021-09-0916 citations

Navafenterol (AZD8871) in healthy volunteers: safety, tolerability and pharmacokinetics of multiple ascending doses of this novel inhaled, long-acting, dual-pharmacology bronchodilator, in two phase I, randomised, single-blind, placebo-controlled studies.

2020-09-093 citations

Multiple ascending inhaled doses of AZD8871 in healthy males

2018-09-15